Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)

a technology of immunoglobulin-like receptors and family members, which is applied in the field of family of immunoregulators designated leukocyte immunoglobulin-like receptors, can solve the problems of less able to challenge infected cells or cancer cells of immune systems with a predominance of inhibitory signals, and achieve the effect of downregulating cell function

Inactive Publication Date: 2006-04-13
IMMUNEX CORP
View PDF6 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention provides a new family of immunoreceptor molecules, designated as LIR polypeptides, which are involved in regulating the immune system. The invention includes DNA sequences encoding LIR family members and their deduced amino acid sequences, as well as polypeptides that hybridize to specific DNA or RNA sequences. The invention also includes recombinant expression vectors containing DNA encoding LIR family members. The invention further includes processes for producing LIR polypeptides by culturing host cells transformed with a recombinant expression vector and recovering the expressed LIR polypeptide. The invention also provides agonistic and antagonistic antibodies to LIR family members, as well as fusion proteins that combine a soluble portion of an LIR family member with the Fc portion of Ig. The invention suggests that disorders associated with failure of a negative signaling LIR to downregulate cell function can be treated by administering an agonistic antibody, while disorders associated with disease states associated with suppressed immune function can be treated by administering a soluble form of the negative signaling LIR. Conversely, disorders associated with failure of a activatory signaling LIR can be treated by administering an agonistic antibody of the activatory receptor, while disorders associated with autoimmune function can be treated by administering a soluble form of the activatory receptor."

Problems solved by technology

Systems with a predominance of activatory signals will lead to autoimmunity and inflammation.
Immune systems with a predominance of inhibitory signals are less able to challenge infected cells or cancer cells.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Isolating and Expressing Viral Protein

[0110] DNA encoding P3G2 polypeptide of the present invention was identified by isolating and expressing a viral glycoprotein, UL18, known to be expressed on cells infected with HCMV, and then expressing and using a UL18 / Fc fusion protein to search for UL18 receptors. DNA encoding UL18 and its amino acid sequence are known and described in Beck, S., B. G. Barrell, Nature 331:269-272, 1988. The following describes isolating UL18 and preparing the UL18 / Fc fusion protein.

[0111] Using standard techniques, total RNA was isolated from Human Foreskin Fibroblasts infected with HCMV (AD169) at three different transcription stages-immediate early (1E, 8 p.i.h.), early (24 p.i.h.) and late (48 p.i.h.). Because UL18 is known to be transcribed early in the infection, the IE total RNA was polyA+ selected and used to construct an HCMV-IE cDNA library using a cDNA kit according to the manufacturer's instructions (Pharmacia TIME SAVER cDNA Kit). In order to is...

example 2

Screening Cell Lines for Binding to UL18

[0117] The sUL18 / Fc protein isolated as described in Example I was used to screen cells lines to which it binds using quantitative binding studies according to standard flow cytometry methodologies. For each cell line screened, the procedure involved incubating approximately 100,000 of the cells blocked with 2% FCS (fetal calf serum), 5% normal goat serum and 5% rabbit serum in PBS for 1 hour. Then the blocked cells were incubated with 5pg / mL of sUL18 / Fc fusion protein in 2% FCS, 5% goat serum and 5% rabbit serum in PBS. Following the incubation the sample was washed 2 times with FACS buffer (2% FCS in PBS) and then treated with mouse anti human Fc / biotin (purchased from Jackson Research) and SAPE (streptavidin-phycoerythrin purchased from Molecular Probes). This treatment causes the anti human Fc / biotin to bind to any bound sUL18 / Fc and the SAPE to bind to the anti human Fc / biotin resulting in a fluorescent identifying label on sUL18 / Fc whic...

example 3

Isolating a P3G2 cDNA and Polypeptide

[0118] The following describes screening cDNA of one of the cell lines found to bind UL18 and the isolation of a novel polypeptide expressed by the cell line. A CB23 cDNA library in the mammalian expression vector pDC406, prepared as described in U.S. Pat. No. 5,350,683 (incorporated herein by reference) was obtained and plasmid DNA was isolated from pools consisting of approximately 2,000 clones per pool. The isolated DNA was transfected into CV1-EBNA cells (ATCC CRL 10478) using DEAE-dextran followed by chloroquine treatment. The CV1-EBNA cells were maintained in complete medium (Dulbecco's modified Eagles′ media containing 10% (v / v) fetal calf serum, 50 U / mL penicillin, 50 U / mL streptomycin, and 2 mM L-glutamine) and were plated to a density of approximately 2×105 cells / well in single-well chambered slides. The slides had been pre-treated with 1 mL of a solution of 10 μg / mL human fibronectin in PBS for 30 minutes followed by a single washing ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
hybridizing temperatureaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridize to oligonucleotide probes having defined sequences, processes for producing polypeptides of the LIR family, and antagonistic antibodies to LIR family members. LIR family members can be used to treat autoimmune diseases and disease states associated with suppressed immune function.

Description

[0001] This application is a continuation of U.S. application Ser. No. 10 / 143,618 filed on May 8, 2002, which is incorporated herein by reference.BACKGROUND OF THE INVENTION [0002] Immune system cellular activity is controlled by a complex network of cell surface interactions and associated signaling processes. When a cell surface receptor is activated by its ligand a signal is sent to the cell, and, depending upon the signal transduction pathway that is engaged, the signal can be inhibitory or activatory. For many receptor systems cellular activity is regulated by a balance between activatory signals and inhibitory signals. In some of these it is known that positive signals associated with the engagement of a cell surface receptor by its ligand are downmodulated or inhibited by negative signals sent by the engagement of a different cell surface receptor by its ligand. [0003] The biochemical mechanisms of these positive and negative signaling pathways have been studied for a number ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K14/715C07H21/04C12P21/06A61K39/00
CPCC07K14/70503A61P37/00
Inventor COSMAN, DAVID
Owner IMMUNEX CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com